KUNMING LONGJIN PHARMACEUTICAL CO., LTD.

Kunming Longjin Pharmaceutical Co., Ltd.

002750

CNE1000021X8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-06-05 EDT			5-day change	1st Jan Change
1.92 ^CNY	-4.95%		-22.58%	-80.80%

04-29	Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-29	Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Yunnan Longjin Fantian Biological Technology Co., Ltd. announced that it has received CNY 48 million in funding from Kunming Longjin Pharmaceutical Co., Ltd.

September 20, 2020

On September 21, 2020, Yunnan Longjin Fantian Biological Technology Co., Ltd. closed the transaction.

Latest news about Kunming Longjin Pharmaceutical Co., Ltd.

Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Kunming Longjin Pharmaceutical Co., Ltd. Approves Board Elections	01-04	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-20	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-29	CI
Kunming Longjin Pharmaceutical's Shareholder Plans to Cut 6% Stake	22-01-12	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-30	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First quarter Ended March 31, 2021	21-04-27	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-14	CI
Longjin Approves Election of Directors	21-01-04	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-28	CI
Yunnan Longjin Fantian Biological Technology Co., Ltd. announced that it has received CNY 48 million in funding from Kunming Longjin Pharmaceutical Co., Ltd.	20-09-20	CI
Yunnan Longjin Fantian Biological Technology Co., Ltd. announced that it expects to receive CNY 48 million in funding from Kunming Longjin Pharmaceutical Co., Ltd.	20-08-31	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-24	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-28	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-13	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019	19-10-23	CI
Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-25	CI

Chart Kunming Longjin Pharmaceutical Co., Ltd.

Duration

Period

Chart Kunming Longjin Pharmaceutical Co., Ltd.

More charts

Kunming Longjin Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and sales of natural botanical and chemical lyophilized powder injection. The Company's products cover traditional Chinese medicine, biochemical medicine and chemical medicine, which including cardio-cerebral vascular medicine, digestive system medicine, immune system medicine, vitamins, mineral enteral and parenteral nutrition medicines. The main products of which is breviscapine injection. The Company conducts its businesses primarily within the domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
KUNMING LONGJIN PHARMACEUTICAL CO., LTD.	-80.80%	106M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.64%	42.33B
OTSUKA HOLDINGS CO., LTD.	+21.25%	22.47B
SANDOZ GROUP AG	+18.63%	15.25B
ZYDUS LIFESCIENCES LIMITED	+53.19%	12.6B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.11%	6.71B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.27%	5.47B
GEDEON RICHTER	+6.91%	4.78B